Stocktoria
Adagene Inc. ADAG
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-02-09
Adagene Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -279.5% | -34835.4% | -131.0% | -903.1% | -711.2% |
| Net margin | -229.6% | -32386.4% | -104.6% | -860.6% | -719.2% |
| Return on assets | -22.5% | -37.4% | -16.4% | -52.5% | -38.6% |
| Return on equity | -49.8% | -66.2% | -26.9% | -96.2% | -46.7% |
| Debt / equity | 0.03× | 0.01× | 0.19× | 0.17× | 0.02× |
| Current ratio | 3.07 | 2.30 | 3.61 | 2.71 | 6.24 |
| Revenue growth | 7332.8% | -99.4% | 94.9% | -8.7% | 1351.7% |
Source: SEC EDGAR filings · CIK 0001818838 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.